Source: International Congress 2014 – ILDs 1
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Korfei, S. Skwarna, I. Henneke, O. Klymenko, G. Dahlem, S. Ziegler, D. von der Beck, W. Klepetko, L. Fink, W. Seeger, O. Krämer, A. Guenther (Giessen, Mainz, Greifenstein, Germany; Vienna, Austria). Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone. Eur Respir J 2014; 44: Suppl. 58, 736

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Retinoic acid-related orphan receptor-a (Rora) expression in patients with fibrotic interstitial pneumonias: A lung tissue study Source: International Congress 2014 – IPF and surroundings Year: 2014 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Regulation and localization of the telomerase enzyme-complex and the shelterin-telosom-complex in sporadic idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014